Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps in Intraoperative Surgical Hemostasis

Trial Profile

A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps in Intraoperative Surgical Hemostasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen/thrombin (Primary) ; Gelatin
  • Indications Surgical blood loss
  • Focus Registrational; Therapeutic Use
  • Acronyms FINISH-3
  • Sponsors ProFibrix
  • Most Recent Events

    • 30 Apr 2015 Based on the results of this trial, the US FDA has approved Raplixa (fibrin sealant) and the RaplixaSpray device to provide adjunctive haemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques is ineffective or impractical, according to a media release from The Medicines Company.
    • 30 Mar 2015 According to a media release from The Medicines Company, the EC has granted marketing authorization for fibrinogen/thrombin [Raplixa], followed by positive opinion by the CHMP of the EMA.
    • 28 Oct 2014 Results published in a media release from The Medicines Company.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top